Qiuli Li

Dr. Qiuli Li

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2020 in Cells
Verified
Journal Article
Open access
PDF file
PSPooja Shah
Pooja Shah
CHChenfei Huang
Chenfei Huang
QLQiuli Li
Qiuli Li
Sawad KaziSawad Kazi
Sawad Kazi
LBLauren A. Byers
Lauren A. Byers
MFMitchell J. Frederick
Mitchell J. Frederick
Biomarker-driven targeted therapies are lacking for head and neck squamous cell carcinoma (HNSCC), which is common and lethal. Efforts to develop such therapies are hindered by a genomic landscape dominated by the loss of tumor suppressor function, including NOTCH1 that is frequently mutated in HNSCC. Clearer understanding of NOTCH1 signaling in HNSCCs is crucial to clinically targeting this pathway. Structural characterization of NOTCH1 mutations in HNSCC demonstrates that most are predicted to cause loss of function, in agreement with NOTCH1’s role as a tumor suppressor in this cancer. Experimental manipulation of NOTCH1 signaling in HNSCC cell lines harboring either mutant or wild-type NOTCH1 further supports a tumor suppressor function. Additionally, the loss of NOTCH1 signaling can drive HNSCC tumorigenesis and clinical aggressiveness. Our recent data suggest that NOTCH1 controls genes involved in early differentiation that could have different phenotypic consequences depending on the cancer’s genetic background, including acquisition of pseudo-stem cell-like properties. The presence of NOTCH1 mutations may predict response to treatment with an immune checkpoint or phosphatidylinositol 3-kinase inhibitors. The latter is being tested in a clinical trial, and if validated, it may lead to the development of the first biomarker-driven targeted therapy for HNSCC.

21 September 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
YLYin Li
Yin Li
JTJiahe Tian
Jiahe Tian
KJKe Jiang
Ke Jiang
ZWZhongyu Wang
Zhongyu Wang
SGSongbo Gao
Songbo Gao
QLQiuli Li
Qiuli Li
Background: The 2015 American Thyroid Association guidelines proposed recurrence risk stratification of differentiated thyroid carcinoma, including papillary thyroid carcinoma (PTC), but this stratification excluded non–initial treatment patients with worse outcomes. This study aimed to explore the potential risk factors for recurrence in PTC and develop a predictive model for both initial and non–initial treatment of patients with PTC.Methods: A total of 955 patients were included in this study. Differences between the recurrence (−) and recurrence (+) groups were compared. The 955 patients were randomized into two groups: the training group (671 cases) and the validation group (284 cases). All variables were selected using the LASSO regression analysis. A nomogram was developed based on the results of the univariate and multivariate logistic regression analyses. The nomogram performance was evaluated using discrimination and calibration.Results: Patients aged ≥55 years, extranodal extension (ENE), metastatic LN ratio (LNR) >0.5, and non–initial treatment were identified as potential risk factors for recurrence through LASSO regression and univariate and multivariate analyses. The receiver operating characteristic curve (ROC curve) showed high efficiency, with an area under the ROC curve (AUC) of 0.819 (95% confidence interval [CI], 0.729–0.909) and 0.818 (95% CI, 0.670–0.909) in the training and validation groups, respectively. The calibration curve indicated that the nomogram had a good consistency.Conclusion: In patients with PTC, age ≥55 years, ENE, LNR >0.5, and non–initial treatment are potential risk factors for recurrence. The predictive model of recurrence was confirmed to be a practical and convenient tool for clinicians to accurately predict PTC recurrence.

1 February 2014 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
SLS. Lin
S. Lin
HHH. Huang
H. Huang
XLXuekui Liu
Xuekui Liu
QLQiuli Li
Qiuli Li
AYAnkui Yang
Ankui Yang
YCYan-Feng Chen
Yan-Feng Chen

30 March 2012 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
TJTing Jin
Ting Jin
XHXin Hua
Xin Hua
HLHui Lin
Hui Lin
LGLi-Bing Guo
Li-Bing Guo
NGNan Ge
Nan Ge
WHWei-Han Hu
Wei-Han Hu
Background: This study was designed to determine the pattern and correlation between expression of the HIF-1α transcriptional targets TGM2 and BNIP3 in laryngeal cancer, and investigate the association of BNIP3 and TGM2 with clinical outcome in laryngeal squamous cell carcinoma (SCC) patients receiving postoperative radiotherapy. Methods: Immunostaining with antibodies specific to BNIP3 and TGM2 was performed in formalin-fixed, paraffin-embedded specimens from 148 laryngeal SCC patients. BNIP3 and TGM2 expression was scored as high or low, based on the number of tumor cells stained and the staining intensity. All patients received postoperative radiotherapy. Patient follow up and clinicopathological data were compared using the Chi-squared test, univariate and multivariate analyses, and survival curves were generated using the Kaplan-Meier method and log-rank test. Results: The 3, 5 and 10-year overall survival rates (OS) for all patients were 77.7%, 71.6%, 56.4%, respectively. Primary tumor site, T stage, overall stage, lymph-node metastasis, BNIP3 expression and TGM2 expression were significant prognostic factors for OS in univariate analysis. Negative cervical lymph nodes, high BNIP3 expression and low TGM2 expression were independent prognostic factors of improved OS in multivariate analysis. BNIP3 expression correlates with TGM2 expression in laryngeal SCC (P = 0.012). Conclusions: This study indicates that lymph-node metastasis, BNIP3 expression and TGM2 expression are independent prognostic factors in laryngeal SCC patients receiving postoperative radiotherapy. Further studies are required to investigate how BNIP3 and/or TGM2 influence the prognosis of laryngeal SCC patients treated with postoperative radiotherapy, and to determine how TGM2 and BNIP3 expression are regulated.

1 October 2014 in British Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
CSChuanzheng Sun
Chuanzheng Sun
ZHZedong Hu
Zedong Hu
ZZZhaoming Zhong
Zhaoming Zhong
YJYue Jiang
Yue Jiang
RSRuimei Sun
Ruimei Sun
QLQiuli Li
Qiuli Li

8 July 2011 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
QLQiuli Li
Qiuli Li
FCFu-Jin Chen
Fu-Jin Chen
RLRenchun Lai
Renchun Lai
ZGZhu-Ming Guo
Zhu-Ming Guo
RLRongzhen Luo
Rongzhen Luo
AYAn-Kui Yang
An-Kui Yang